Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma

NCT06659770 is registered in ClinicalTrials.gov with CARsgen Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06659770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06659770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Phase
Observational
Overall status
Not yet recruiting
Start date
October 31, 2024
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma